Castrate resistant Prostate Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, Companies by DelveInsight

Posted on
by

Castrate resistant Prostate Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, Companies by DelveInsight

DelveInsight’s, “Castrate Resistant Prostate Cancer Pipeline Insight” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostate Cancer pipeline landscape. It covers the Castrate Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Castrate Resistant Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Castrate Resistant Prostate Cancer Pipeline Report to explore emerging therapies, key Castrate Resistant Prostate Cancer Companies, and future Castrate Resistant Prostate Cancer treatment landscapes @ Castrate Resistant Prostate Cancer Pipeline Outlook Report

Key Takeaways from the Castrate Resistant Prostate Cancer Pipeline Report

  • In February 2025:- Daniel George, MD- The primary goal is to prospectively estimate the median PFS of African American and Caucasian men with mCRPC taking apalutamide, abiraterone acetate, and prednisone. Secondary objectives include: PSA kinetics: to determine the duration of PSA response, time to nadir, and percent of men who achieve a PSA < 0.1; Radiographic assessments: to estimate the rate of objective response and incidence of bone flares; Safety (NCI CTC v4.0) and tolerability, particularly incidence and grade of hypertension in the two populations.
  • In February 2025:- Alliance Foundation Trials, LLC.:- This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with metastatic and non-metastatic castration resistant prostate cancer (CRPC) or metastatic hormone sensitive prostate cancer (HSPC). Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg orally daily or darolutamide 600 mg orally twice daily, in combination with standard LHRH agonist based treatment. Cognitive assessments will be performed using modules from Cambridge Neuropsychological Test Automated Battery (CANTAB) an internationally recognized software for assessing cognitive function and impairment.
  • In February 2025:- Dana-Farber Cancer Institute:- This study is comparing the safety and effectiveness of abiraterone acetate alone, followed by the addition of prednisone (when the participant’s disease worsens or the physician feels it would lessen symptoms of toxicity) versus the current approved treatment regimen which involves the concomitant use of prednisone in conjunction with abiraterone acetate. Additionally, this study is also examining why participants stop responding to treatment with abiraterone acetate by evaluating blood and tissue.
  • DelveInsight’s Castrate Resistant Prostate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostate Cancer treatment.
  • The leading Castrate Resistant Prostate Cancer Companies such as Janssen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma and others.
  • Promising Castrate Resistant Prostate Cancer pipeline therapies such as AZD4635, Durvalumab, Cabazitaxel, tomivosertib (eFT508), Atezolizumab, Radium-223 Dichloridem, and others.

Discover how the Castrate Resistant Prostate Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Castrate Resistant Prostate Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Castrate Resistant Prostate Cancer Clinical Trials and Studies

Castrate Resistant Prostate Cancer Emerging Drugs

  • Niraparib: Janseen

Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.

  • Nivolumab: Bristol-Myers Squibb

Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.

The Castrate Resistant Prostate Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Castrate Resistant Prostate Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Castrate Resistant Prostate Cancer Treatment.
  • Castrate Resistant Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Castrate Resistant Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Castrate Resistant Prostate Cancer market.

Get a detailed analysis of the latest innovations in the Castrate Resistant Prostate Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Castrate Resistant Prostate Cancer Unmet Needs

Castrate Resistant Prostate Cancer Companies

Janssen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma and others.

Castrate Resistant Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Castrate Resistant Prostate Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Download DelveInsight’s latest report to gain strategic insights into upcoming Castrate Resistant Prostate Cancer Therapies and key Castrate Resistant Prostate Cancer Developments @ Castrate Resistant Prostate Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Castrate Resistant Prostate Cancer Pipeline Report

  • Coverage- Global
  • Castrate Resistant Prostate Cancer Companies- Janssen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma and others.
  • Promising Castrate Resistant Prostate Cancer pipeline therapies such as AZD4635, Durvalumab, Cabazitaxel, tomivosertib (eFT508), Atezolizumab, Radium-223 Dichloridem, and others.
  • Castrate Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Castrate Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Castrate Resistant Prostate Cancer drug development? Find out in DelveInsight’s exclusive Castrate Resistant Prostate Cancer Pipeline Report—access it now! @ Castrate Resistant Prostate Cancer Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Castrate Resistant Prostrate Cancer: Overview
  4. Causes
  5. Mechanism of Action
  6. Signs and Symptoms
  7. Diagnosis
  8. Disease Management
  9. Pipeline Therapeutics
  10. Comparative Analysis
  11. Therapeutic Assessment
  12. Assessment by Product Type
  13. Assessment by Stage and Product Type
  14. Assessment by Route of Administration
  15. Assessment by Stage and Route of Administration
  16. Assessment by Molecule Type
  17. Assessment by Stage and Molecule Type
  18. Castrate Resistant Prostrate Cancer – DelveInsight’s Analytical Perspective
  19. In-depth Commercial Assessment
  20. Castrate Resistant Prostrate Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
  21. Castrate Resistant Prostrate Cancer Collaboration Deals
  22. Company-Company Collaborations (Licensing / Partnering) Analysis
  23. Company-University Collaborations (Licensing / Partnering) Analysis
  24. Late Stage Products (Phase III)
  25. Comparative Analysis
  26. Niraparib: Janseen
  27. Product Description
  28. Research and Development
  29. Product Development Activities
  30. Mid Stage Products (Phase II)
  31. Comparative Analysis
  32. ZEN003694: Newsoara Biopharma
  33. Product Description
  34. Research and Development
  35. Product Development Activities
  36. Drug profiles in the detailed report…..
  37. Early Stage Products (Phase I)
  38. Comparative Analysis
  39. EPI7386: ESSA Pharma
  40. Product Description
  41. Research and Development
  42. Product Development Activities
  43. Drug profiles in the detailed report…..
  44. Pre-clinical and Discovery Stage Products
  45. Comparative Analysis
  46. Drug Name: Company Name
  47. Product Description
  48. Research and Development
  49. Product Development Activities
  50. Drug profiles in the detailed report…..
  51. Inactive Products
  52. Comparative Analysis
  53. Castrate Resistant Prostrate Cancer Key Companies
  54. Castrate Resistant Prostrate Cancer Key Products
  55. Castrate Resistant Prostrate Cancer- Unmet Needs
  56. Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
  57. Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
  58. Castrate Resistant Prostrate Cancer Analyst Views
  59. Castrate Resistant Prostrate Cancer Key Companies
  60. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sepsis-market-insight